[go: up one dir, main page]

ZA200800025B - Use of soluble guanylate cyclase activators for treating reperfusion damage - Google Patents

Use of soluble guanylate cyclase activators for treating reperfusion damage

Info

Publication number
ZA200800025B
ZA200800025B ZA200800025A ZA200800025A ZA200800025B ZA 200800025 B ZA200800025 B ZA 200800025B ZA 200800025 A ZA200800025 A ZA 200800025A ZA 200800025 A ZA200800025 A ZA 200800025A ZA 200800025 B ZA200800025 B ZA 200800025B
Authority
ZA
South Africa
Prior art keywords
guanylate cyclase
soluble guanylate
reperfusion damage
cyclase activators
treating reperfusion
Prior art date
Application number
ZA200800025A
Other languages
English (en)
Inventor
Krahn Thomas
Stasch Johannes-Peter
Weimann Gerrit
Thielemann Wolfgang
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ZA200800025B publication Critical patent/ZA200800025B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200800025A 2005-07-06 2008-01-02 Use of soluble guanylate cyclase activators for treating reperfusion damage ZA200800025B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005031576A DE102005031576A1 (de) 2005-07-06 2005-07-06 Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Reperfusionsschäden

Publications (1)

Publication Number Publication Date
ZA200800025B true ZA200800025B (en) 2009-09-30

Family

ID=37433912

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800025A ZA200800025B (en) 2005-07-06 2008-01-02 Use of soluble guanylate cyclase activators for treating reperfusion damage

Country Status (14)

Country Link
US (1) US20090298822A1 (xx)
EP (1) EP1901730A1 (xx)
JP (1) JP2009500365A (xx)
KR (1) KR20080033238A (xx)
CN (1) CN101257901A (xx)
AU (1) AU2006286896A1 (xx)
BR (1) BRPI0612685A2 (xx)
CA (1) CA2614088A1 (xx)
DE (1) DE102005031576A1 (xx)
IL (1) IL188584A0 (xx)
MX (1) MX2008000276A (xx)
RU (1) RU2432948C2 (xx)
WO (1) WO2007025595A1 (xx)
ZA (1) ZA200800025B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026392A1 (de) 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
US8765769B2 (en) * 2010-07-09 2014-07-01 Bayer Intellectual Property Gmbh Ring-fused 4-aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases
EP2729476B1 (de) * 2011-07-06 2017-08-23 Bayer Intellectual Property GmbH Heteroaryl-substituierte pyrazolopyridine und ihre verwendung als stimulatoren der löslichen guanylatcyclase
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN105026405B (zh) * 2013-03-01 2017-08-08 拜耳制药股份公司 苄基‑取代的吡唑并吡啶及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US173514A (en) * 1876-02-15 Improvement in call-bells
KR100720844B1 (ko) * 1998-07-08 2007-05-25 사노피-아벤티스 도이칠란트 게엠베하 황 치환된 설포닐아미노카복실산 n-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
AU2002360346A1 (en) * 2001-11-06 2003-05-19 Buck Institute Neuroglobin is up-regulated by and protects neuronsfrom hypoxic-ischemic injury
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10351903A1 (de) * 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
US20050255178A1 (en) * 2004-02-04 2005-11-17 Bloch Kenneth D Enhancing the effectiveness of an inhaled therapeutic gas
US20080138444A1 (en) * 2004-10-05 2008-06-12 Bayer Healthcare Ag Method For Treating Bronchoconstriction and Pulmonary Vaso-Constriction

Also Published As

Publication number Publication date
IL188584A0 (en) 2008-06-05
KR20080033238A (ko) 2008-04-16
RU2008103549A (ru) 2009-08-20
EP1901730A1 (de) 2008-03-26
DE102005031576A1 (de) 2007-01-25
MX2008000276A (es) 2008-03-19
BRPI0612685A2 (pt) 2010-11-30
WO2007025595A1 (de) 2007-03-08
RU2432948C2 (ru) 2011-11-10
JP2009500365A (ja) 2009-01-08
AU2006286896A1 (en) 2007-03-08
CN101257901A (zh) 2008-09-03
CA2614088A1 (en) 2007-03-08
US20090298822A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
IL222698A0 (en) Benzazole derivatives, compositions, and methods of use as b- secretase inhibitors
IL192053A0 (en) 2-adamantylurea derivatives as selective 11??-hsd1 inhibitors
ZA200710951B (en) Piperidinyl-substituted isoquinolone derivatives as Rhokinase inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
SI1910348T1 (sl) Spojine benzotiazola in azabenzotiazola, uporabne kot kinazni inhibitorji
IL214559A0 (en) Soluble guanylate cyclase activators
IL189048A (en) Uranium derivatives as 3-gsk inhibitors
EP1960781A4 (en) COMPOSITIONS AND METHODS FOR DETECTING PHOSPHOMONOESTERS
EP2373317A4 (en) SOLUBLE GUANYLATE CYCLASE ACTIVATORS
PT2069336E (pt) Derivados de piridin-4-ilo como agentes imunomoduladores
ZA200801822B (en) Pyrazine derivatives and use as p13k inhibitors
PL1846394T3 (pl) Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy
IL177101A0 (en) Quinoline derivatives for use as mycobacterial inhibitors
ZA200804611B (en) Methods for the use of branched chain amino acids
ZA200900807B (en) Isoserine derivatives for use as coagulation factor IXa inhibitors
ZA200800025B (en) Use of soluble guanylate cyclase activators for treating reperfusion damage
PL2065206T3 (pl) Urządzenie do uszlachetniania detali
IL190619A0 (en) Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases
PT1937262T (pt) Composição para utilização no tratamento de dismotilidade gastrointestinal
PL1693152T3 (pl) Urządzenie do wykończającej obróbki krawędziowych listew na płytowych przedmiotach obrabianych
ZA200703307B (en) Indol derivatives as inhibitors of soluble adenylyl cyclase
IL184786A0 (en) Amide derivatives as ppar activators
IL197505A0 (en) TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS
EP1890690A4 (en) MAO-B INHIBITORS FOR TREATING OBESITY